Lindsey Moore
Family · Muscle Shoals, ALNPI 1528433844
Payments from drug & device makers
Across 281 payments — averaging $34.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$7K
- Lilly USA, LLC$482
- AbbVie$233
- Amgen$210
- Dexcom, Inc.$203
- Takeda Pharmaceuticals U.S.A., Inc.$180
- plus $1K from 25 others
What the payments were for
- Consulting fees$5,60858%
- Food & beverage$4,04442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 134 | $7,204 |
| Lilly USA, LLC | 37 | $482 |
| AbbVie | 23 | $233 |
| Amgen | 4 | $210 |
| Dexcom, Inc. | 6 | $203 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $180 |
| AstraZeneca | 10 | $152 |
| Corcept Therapeutics | 7 | $134 |
| Pfizer | 7 | $115 |
| Atricure, Inc. | 1 | $110 |
| Bayer | 5 | $76 |
| Bausch Health US, LLC | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Boehringer Ingelheim | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $41 |
| Merck | 3 | $38 |
| Inspire Medical Systems, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Medtronic | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,652 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $164,262 |
| MounjaroTirzepatide | 107 | $117,389 |
| FarxigaDapagliflozin Propanediol | 22 | $15,178 |
| Metformin Hcl ErMetformin Hcl | 220 | $1,206 |
| Bupropion XlBupropion Hcl | 42 | $685 |
| Pantoprazole Sodium | 48 | $486 |
| Levothyroxine Sodium | 74 | $453 |
| Topiramate | 40 | $328 |
| Fluticasone Propionate | 23 | $268 |
| Spironolactone | 21 | $252 |
| Diclofenac Sodium | 13 | $245 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $202 |
| Ondansetron Hcl | 31 | $202 |
| Esomeprazole Magnesium | 15 | $185 |
| Simvastatin | 19 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $7,204 | $164,262148 claims |
| Lilly USA, LLCMounjaro | $482 | $117,389107 claims |
| AstraZenecaFarxiga | $152 | $15,17822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Muscle Shoals
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.